Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing
In the present work, we investigated if an impairment of dopaminergic neurons after subchronic haloperidol treatment might be a possible physiopathologic substrate of the ‘early onset’ vacuous chewing movements (VCMs) in rats. For this purpose, different antipsychotics were used to analyse a possibl...
Gespeichert in:
Veröffentlicht in: | The European journal of neuroscience 2002-04, Vol.15 (7), p.1187-1196 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1196 |
---|---|
container_issue | 7 |
container_start_page | 1187 |
container_title | The European journal of neuroscience |
container_volume | 15 |
creator | Marchese, Giorgio Casu, Maria Antonietta Bartholini, Francesco Ruiu, Stefania Saba, Pierluigi Gessa, Gian Luigi Pani, Luca |
description | In the present work, we investigated if an impairment of dopaminergic neurons after subchronic haloperidol treatment might be a possible physiopathologic substrate of the ‘early onset’ vacuous chewing movements (VCMs) in rats. For this purpose, different antipsychotics were used to analyse a possible relationship between VCMs development and morphological alterations of tyrosine‐hydroxylase‐immunostained (TH‐IM) neurons.
Rats treated twice a day with haloperidol displayed a significant increase of VCMs that was both time‐ (2–4 weeks) and dose (0.1–1 mg/kg) dependent. Immunocytochemical analysis showed a shrinkage of TH‐IM cell bodies in substantia nigra pars compacta and reticulata and a reduction of TH‐immunostaining in the striatum of haloperidol treated rats with the arising of VCMs. No differences were observed in TH‐IM neurons of ventral tegmental area and nucleus accumbens vs. control rats. The atypical antipsychotics risperidone (2 mg/kg, twice a day), amisulpride (20 mg/kg, twice a day) and clozapine (10 mg/kg, twice a day) did not produce any nigro‐striatal morphological changes or VCMs. TH‐IM nigro‐striatal neuron morphological alterations and VCMs were still present after three days of withdrawal in rats treated for four weeks with haloperidol (1 mg/kg). Both the main morphological changes and the behavioural correlate disappeared after three weeks of withdrawal. These results suggest that haloperidol induces a morphological impairment of the dopaminergic nigro‐striatal neurons which is directly associated with the arising, permanency and disappearance of VCMs in rats. |
doi_str_mv | 10.1046/j.1460-9568.2002.01944.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808661568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1808661568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4364-76830014354097147342004fa0edaaf3749c1a15197c7392d21ce3978e190ea23</originalsourceid><addsrcrecordid>eNqNUs2O0zAQjhCILQuvgHxbLgl27Pz4wAGtlgVUlsMugps1daatSxIH26HN2_FoOG21XDnZmu9nxvM5SQijGaOifLvLmChpKouyznJK84wyKUR2eJIsHoGnyYLKgqc1K39cJC-831FK61IUz5MLxmSdl7lcJH_ux1Wqt872RpPgEEKHfSB7E7ZEt-C90dCS1RhIbwOBMA3HAvTBDH7SWxuM9mRwthk1etJZN2xtazdHlt5Cv4lV0xMH0cFsnE19cAZCRBs7QGd6dJFMehzjDJ40xqEO7UQcthCwIcGSKwQXKxHGcEV-gx7t6KM57k2_eZk8W0Pr8dX5vEy-fbh5uP6YLr_efrp-v0y14KVIq7LmlDLBC0FlxUTFRVycWAPFBmDNKyE1A1YwWemKy7zJmUYuqxqZpAg5v0zenHzjW3-N6IPqjNfYttBjHEexOi63ZHHxkVqfqNpZ7x2u1eBMB25SjKo5P7VTc0xqjknN-aljfuoQpa_PXcZVh80_4TmwSHh3IuxNi9N_G6ubz3fzLerTk974gIdHPbifqqx4Vajvd7fqPn6Uh0os1Rf-F0ZivRI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1808661568</pqid></control><display><type>article</type><title>Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Marchese, Giorgio ; Casu, Maria Antonietta ; Bartholini, Francesco ; Ruiu, Stefania ; Saba, Pierluigi ; Gessa, Gian Luigi ; Pani, Luca</creator><creatorcontrib>Marchese, Giorgio ; Casu, Maria Antonietta ; Bartholini, Francesco ; Ruiu, Stefania ; Saba, Pierluigi ; Gessa, Gian Luigi ; Pani, Luca</creatorcontrib><description>In the present work, we investigated if an impairment of dopaminergic neurons after subchronic haloperidol treatment might be a possible physiopathologic substrate of the ‘early onset’ vacuous chewing movements (VCMs) in rats. For this purpose, different antipsychotics were used to analyse a possible relationship between VCMs development and morphological alterations of tyrosine‐hydroxylase‐immunostained (TH‐IM) neurons.
Rats treated twice a day with haloperidol displayed a significant increase of VCMs that was both time‐ (2–4 weeks) and dose (0.1–1 mg/kg) dependent. Immunocytochemical analysis showed a shrinkage of TH‐IM cell bodies in substantia nigra pars compacta and reticulata and a reduction of TH‐immunostaining in the striatum of haloperidol treated rats with the arising of VCMs. No differences were observed in TH‐IM neurons of ventral tegmental area and nucleus accumbens vs. control rats. The atypical antipsychotics risperidone (2 mg/kg, twice a day), amisulpride (20 mg/kg, twice a day) and clozapine (10 mg/kg, twice a day) did not produce any nigro‐striatal morphological changes or VCMs. TH‐IM nigro‐striatal neuron morphological alterations and VCMs were still present after three days of withdrawal in rats treated for four weeks with haloperidol (1 mg/kg). Both the main morphological changes and the behavioural correlate disappeared after three weeks of withdrawal. These results suggest that haloperidol induces a morphological impairment of the dopaminergic nigro‐striatal neurons which is directly associated with the arising, permanency and disappearance of VCMs in rats.</description><identifier>ISSN: 0953-816X</identifier><identifier>EISSN: 1460-9568</identifier><identifier>DOI: 10.1046/j.1460-9568.2002.01944.x</identifier><identifier>PMID: 11982629</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science, Ltd</publisher><subject>Amisulpride ; Animals ; Antipsychotic Agents - toxicity ; Clozapine - toxicity ; Dopamine - metabolism ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Dyskinesia, Drug-Induced - metabolism ; Dyskinesia, Drug-Induced - pathology ; Dyskinesia, Drug-Induced - physiopathology ; Haloperidol - toxicity ; Male ; Mastication - drug effects ; Mastication - physiology ; Neostriatum - drug effects ; Neostriatum - metabolism ; Neostriatum - pathology ; Nerve Degeneration - chemically induced ; Nerve Degeneration - metabolism ; Nerve Degeneration - pathology ; Neural Pathways - drug effects ; Neural Pathways - metabolism ; Neural Pathways - pathology ; Neurons - drug effects ; Neurons - metabolism ; Neurons - pathology ; neurotoxicity ; Parkinson ; Rats ; Rats, Sprague-Dawley ; Risperidone - toxicity ; Substance Withdrawal Syndrome - metabolism ; Substance Withdrawal Syndrome - pathology ; Substance Withdrawal Syndrome - physiopathology ; Substantia Nigra - drug effects ; Substantia Nigra - metabolism ; Substantia Nigra - pathology ; Sulpiride - analogs & derivatives ; Sulpiride - toxicity ; tardive dyskinesia</subject><ispartof>The European journal of neuroscience, 2002-04, Vol.15 (7), p.1187-1196</ispartof><rights>Federation of European Neuroscience Societies</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4364-76830014354097147342004fa0edaaf3749c1a15197c7392d21ce3978e190ea23</citedby><cites>FETCH-LOGICAL-c4364-76830014354097147342004fa0edaaf3749c1a15197c7392d21ce3978e190ea23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1460-9568.2002.01944.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1460-9568.2002.01944.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11982629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marchese, Giorgio</creatorcontrib><creatorcontrib>Casu, Maria Antonietta</creatorcontrib><creatorcontrib>Bartholini, Francesco</creatorcontrib><creatorcontrib>Ruiu, Stefania</creatorcontrib><creatorcontrib>Saba, Pierluigi</creatorcontrib><creatorcontrib>Gessa, Gian Luigi</creatorcontrib><creatorcontrib>Pani, Luca</creatorcontrib><title>Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing</title><title>The European journal of neuroscience</title><addtitle>Eur J Neurosci</addtitle><description>In the present work, we investigated if an impairment of dopaminergic neurons after subchronic haloperidol treatment might be a possible physiopathologic substrate of the ‘early onset’ vacuous chewing movements (VCMs) in rats. For this purpose, different antipsychotics were used to analyse a possible relationship between VCMs development and morphological alterations of tyrosine‐hydroxylase‐immunostained (TH‐IM) neurons.
Rats treated twice a day with haloperidol displayed a significant increase of VCMs that was both time‐ (2–4 weeks) and dose (0.1–1 mg/kg) dependent. Immunocytochemical analysis showed a shrinkage of TH‐IM cell bodies in substantia nigra pars compacta and reticulata and a reduction of TH‐immunostaining in the striatum of haloperidol treated rats with the arising of VCMs. No differences were observed in TH‐IM neurons of ventral tegmental area and nucleus accumbens vs. control rats. The atypical antipsychotics risperidone (2 mg/kg, twice a day), amisulpride (20 mg/kg, twice a day) and clozapine (10 mg/kg, twice a day) did not produce any nigro‐striatal morphological changes or VCMs. TH‐IM nigro‐striatal neuron morphological alterations and VCMs were still present after three days of withdrawal in rats treated for four weeks with haloperidol (1 mg/kg). Both the main morphological changes and the behavioural correlate disappeared after three weeks of withdrawal. These results suggest that haloperidol induces a morphological impairment of the dopaminergic nigro‐striatal neurons which is directly associated with the arising, permanency and disappearance of VCMs in rats.</description><subject>Amisulpride</subject><subject>Animals</subject><subject>Antipsychotic Agents - toxicity</subject><subject>Clozapine - toxicity</subject><subject>Dopamine - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Dyskinesia, Drug-Induced - metabolism</subject><subject>Dyskinesia, Drug-Induced - pathology</subject><subject>Dyskinesia, Drug-Induced - physiopathology</subject><subject>Haloperidol - toxicity</subject><subject>Male</subject><subject>Mastication - drug effects</subject><subject>Mastication - physiology</subject><subject>Neostriatum - drug effects</subject><subject>Neostriatum - metabolism</subject><subject>Neostriatum - pathology</subject><subject>Nerve Degeneration - chemically induced</subject><subject>Nerve Degeneration - metabolism</subject><subject>Nerve Degeneration - pathology</subject><subject>Neural Pathways - drug effects</subject><subject>Neural Pathways - metabolism</subject><subject>Neural Pathways - pathology</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Neurons - pathology</subject><subject>neurotoxicity</subject><subject>Parkinson</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Risperidone - toxicity</subject><subject>Substance Withdrawal Syndrome - metabolism</subject><subject>Substance Withdrawal Syndrome - pathology</subject><subject>Substance Withdrawal Syndrome - physiopathology</subject><subject>Substantia Nigra - drug effects</subject><subject>Substantia Nigra - metabolism</subject><subject>Substantia Nigra - pathology</subject><subject>Sulpiride - analogs & derivatives</subject><subject>Sulpiride - toxicity</subject><subject>tardive dyskinesia</subject><issn>0953-816X</issn><issn>1460-9568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUs2O0zAQjhCILQuvgHxbLgl27Pz4wAGtlgVUlsMugps1daatSxIH26HN2_FoOG21XDnZmu9nxvM5SQijGaOifLvLmChpKouyznJK84wyKUR2eJIsHoGnyYLKgqc1K39cJC-831FK61IUz5MLxmSdl7lcJH_ux1Wqt872RpPgEEKHfSB7E7ZEt-C90dCS1RhIbwOBMA3HAvTBDH7SWxuM9mRwthk1etJZN2xtazdHlt5Cv4lV0xMH0cFsnE19cAZCRBs7QGd6dJFMehzjDJ40xqEO7UQcthCwIcGSKwQXKxHGcEV-gx7t6KM57k2_eZk8W0Pr8dX5vEy-fbh5uP6YLr_efrp-v0y14KVIq7LmlDLBC0FlxUTFRVycWAPFBmDNKyE1A1YwWemKy7zJmUYuqxqZpAg5v0zenHzjW3-N6IPqjNfYttBjHEexOi63ZHHxkVqfqNpZ7x2u1eBMB25SjKo5P7VTc0xqjknN-aljfuoQpa_PXcZVh80_4TmwSHh3IuxNi9N_G6ubz3fzLerTk974gIdHPbifqqx4Vajvd7fqPn6Uh0os1Rf-F0ZivRI</recordid><startdate>200204</startdate><enddate>200204</enddate><creator>Marchese, Giorgio</creator><creator>Casu, Maria Antonietta</creator><creator>Bartholini, Francesco</creator><creator>Ruiu, Stefania</creator><creator>Saba, Pierluigi</creator><creator>Gessa, Gian Luigi</creator><creator>Pani, Luca</creator><general>Blackwell Science, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>200204</creationdate><title>Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing</title><author>Marchese, Giorgio ; Casu, Maria Antonietta ; Bartholini, Francesco ; Ruiu, Stefania ; Saba, Pierluigi ; Gessa, Gian Luigi ; Pani, Luca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4364-76830014354097147342004fa0edaaf3749c1a15197c7392d21ce3978e190ea23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Amisulpride</topic><topic>Animals</topic><topic>Antipsychotic Agents - toxicity</topic><topic>Clozapine - toxicity</topic><topic>Dopamine - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Dyskinesia, Drug-Induced - metabolism</topic><topic>Dyskinesia, Drug-Induced - pathology</topic><topic>Dyskinesia, Drug-Induced - physiopathology</topic><topic>Haloperidol - toxicity</topic><topic>Male</topic><topic>Mastication - drug effects</topic><topic>Mastication - physiology</topic><topic>Neostriatum - drug effects</topic><topic>Neostriatum - metabolism</topic><topic>Neostriatum - pathology</topic><topic>Nerve Degeneration - chemically induced</topic><topic>Nerve Degeneration - metabolism</topic><topic>Nerve Degeneration - pathology</topic><topic>Neural Pathways - drug effects</topic><topic>Neural Pathways - metabolism</topic><topic>Neural Pathways - pathology</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Neurons - pathology</topic><topic>neurotoxicity</topic><topic>Parkinson</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Risperidone - toxicity</topic><topic>Substance Withdrawal Syndrome - metabolism</topic><topic>Substance Withdrawal Syndrome - pathology</topic><topic>Substance Withdrawal Syndrome - physiopathology</topic><topic>Substantia Nigra - drug effects</topic><topic>Substantia Nigra - metabolism</topic><topic>Substantia Nigra - pathology</topic><topic>Sulpiride - analogs & derivatives</topic><topic>Sulpiride - toxicity</topic><topic>tardive dyskinesia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marchese, Giorgio</creatorcontrib><creatorcontrib>Casu, Maria Antonietta</creatorcontrib><creatorcontrib>Bartholini, Francesco</creatorcontrib><creatorcontrib>Ruiu, Stefania</creatorcontrib><creatorcontrib>Saba, Pierluigi</creatorcontrib><creatorcontrib>Gessa, Gian Luigi</creatorcontrib><creatorcontrib>Pani, Luca</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>The European journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marchese, Giorgio</au><au>Casu, Maria Antonietta</au><au>Bartholini, Francesco</au><au>Ruiu, Stefania</au><au>Saba, Pierluigi</au><au>Gessa, Gian Luigi</au><au>Pani, Luca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing</atitle><jtitle>The European journal of neuroscience</jtitle><addtitle>Eur J Neurosci</addtitle><date>2002-04</date><risdate>2002</risdate><volume>15</volume><issue>7</issue><spage>1187</spage><epage>1196</epage><pages>1187-1196</pages><issn>0953-816X</issn><eissn>1460-9568</eissn><abstract>In the present work, we investigated if an impairment of dopaminergic neurons after subchronic haloperidol treatment might be a possible physiopathologic substrate of the ‘early onset’ vacuous chewing movements (VCMs) in rats. For this purpose, different antipsychotics were used to analyse a possible relationship between VCMs development and morphological alterations of tyrosine‐hydroxylase‐immunostained (TH‐IM) neurons.
Rats treated twice a day with haloperidol displayed a significant increase of VCMs that was both time‐ (2–4 weeks) and dose (0.1–1 mg/kg) dependent. Immunocytochemical analysis showed a shrinkage of TH‐IM cell bodies in substantia nigra pars compacta and reticulata and a reduction of TH‐immunostaining in the striatum of haloperidol treated rats with the arising of VCMs. No differences were observed in TH‐IM neurons of ventral tegmental area and nucleus accumbens vs. control rats. The atypical antipsychotics risperidone (2 mg/kg, twice a day), amisulpride (20 mg/kg, twice a day) and clozapine (10 mg/kg, twice a day) did not produce any nigro‐striatal morphological changes or VCMs. TH‐IM nigro‐striatal neuron morphological alterations and VCMs were still present after three days of withdrawal in rats treated for four weeks with haloperidol (1 mg/kg). Both the main morphological changes and the behavioural correlate disappeared after three weeks of withdrawal. These results suggest that haloperidol induces a morphological impairment of the dopaminergic nigro‐striatal neurons which is directly associated with the arising, permanency and disappearance of VCMs in rats.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science, Ltd</pub><pmid>11982629</pmid><doi>10.1046/j.1460-9568.2002.01944.x</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0953-816X |
ispartof | The European journal of neuroscience, 2002-04, Vol.15 (7), p.1187-1196 |
issn | 0953-816X 1460-9568 |
language | eng |
recordid | cdi_proquest_miscellaneous_1808661568 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Amisulpride Animals Antipsychotic Agents - toxicity Clozapine - toxicity Dopamine - metabolism Dose-Response Relationship, Drug Drug Administration Schedule Dyskinesia, Drug-Induced - metabolism Dyskinesia, Drug-Induced - pathology Dyskinesia, Drug-Induced - physiopathology Haloperidol - toxicity Male Mastication - drug effects Mastication - physiology Neostriatum - drug effects Neostriatum - metabolism Neostriatum - pathology Nerve Degeneration - chemically induced Nerve Degeneration - metabolism Nerve Degeneration - pathology Neural Pathways - drug effects Neural Pathways - metabolism Neural Pathways - pathology Neurons - drug effects Neurons - metabolism Neurons - pathology neurotoxicity Parkinson Rats Rats, Sprague-Dawley Risperidone - toxicity Substance Withdrawal Syndrome - metabolism Substance Withdrawal Syndrome - pathology Substance Withdrawal Syndrome - physiopathology Substantia Nigra - drug effects Substantia Nigra - metabolism Substantia Nigra - pathology Sulpiride - analogs & derivatives Sulpiride - toxicity tardive dyskinesia |
title | Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A17%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sub-chronic%20treatment%20with%20classical%20but%20not%20atypical%20antipsychotics%20produces%20morphological%20changes%20in%20rat%20nigro-striatal%20dopaminergic%20neurons%20directly%20related%20to%20'early%20onset'%20vacuous%20chewing&rft.jtitle=The%20European%20journal%20of%20neuroscience&rft.au=Marchese,%20Giorgio&rft.date=2002-04&rft.volume=15&rft.issue=7&rft.spage=1187&rft.epage=1196&rft.pages=1187-1196&rft.issn=0953-816X&rft.eissn=1460-9568&rft_id=info:doi/10.1046/j.1460-9568.2002.01944.x&rft_dat=%3Cproquest_cross%3E1808661568%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1808661568&rft_id=info:pmid/11982629&rfr_iscdi=true |